JP2005508940A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508940A5
JP2005508940A5 JP2003533918A JP2003533918A JP2005508940A5 JP 2005508940 A5 JP2005508940 A5 JP 2005508940A5 JP 2003533918 A JP2003533918 A JP 2003533918A JP 2003533918 A JP2003533918 A JP 2003533918A JP 2005508940 A5 JP2005508940 A5 JP 2005508940A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
hydroxy
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003533918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508940A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/032010 external-priority patent/WO2003030886A2/en
Publication of JP2005508940A publication Critical patent/JP2005508940A/ja
Publication of JP2005508940A5 publication Critical patent/JP2005508940A5/ja
Pending legal-status Critical Current

Links

JP2003533918A 2001-10-05 2002-10-04 アルツハイマー病の治療に有用なアリルアミド Pending JP2005508940A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32724301P 2001-10-05 2001-10-05
PCT/US2002/032010 WO2003030886A2 (en) 2001-10-05 2002-10-04 Allylamides useful in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2005508940A JP2005508940A (ja) 2005-04-07
JP2005508940A5 true JP2005508940A5 (enExample) 2006-01-05

Family

ID=23275725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003533918A Pending JP2005508940A (ja) 2001-10-05 2002-10-04 アルツハイマー病の治療に有用なアリルアミド

Country Status (8)

Country Link
US (1) US20050027007A1 (enExample)
EP (1) EP1434580A2 (enExample)
JP (1) JP2005508940A (enExample)
AU (1) AU2002335794A1 (enExample)
BR (1) BR0213138A (enExample)
CA (1) CA2462875A1 (enExample)
MX (1) MXPA04003244A (enExample)
WO (1) WO2003030886A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CN100475786C (zh) * 2005-02-18 2009-04-08 中国科学院上海药物研究所 一类4-羟基戊酰胺类化合物及其制备方法和用途
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
AU2006316620B2 (en) 2005-11-21 2011-03-03 Amgen Inc. Beta-secretase modulators and methods of use
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010030954A1 (en) 2008-09-11 2010-03-18 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8735384B2 (en) 2010-01-19 2014-05-27 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
ES2450568T3 (es) 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
CA2791281A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN111087386B (zh) * 2020-01-02 2020-12-18 牡丹江医学院 一种用于治疗阿尔茨海默病的化合物及其合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52731A1 (en) * 1991-11-08 1998-09-28 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
AU2001259817A1 (en) * 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains

Similar Documents

Publication Publication Date Title
JP2005508940A5 (enExample)
AU2006332677B2 (en) Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2011503045A (ja) Crth2拮抗化合物の使用
JP2005516967A (ja) β−セクレターゼインヒビター
WO2009063215A2 (en) Use of crth2 antagonist compounds
JP2013514368A (ja) 神経変性疾患を処置するための、ppar温存チアゾリジンジオンおよび組み合わせ物
US20110124683A1 (en) Use of CRTH2 Antagonist Compounds
JP2001510154A (ja) カッパアゴニスト化合物、製剤、ならびにそれらによる掻痒の予防法および治療法
JP5674676B2 (ja) 結腸癌発生を予防または低減する方法
US6946474B2 (en) Nitrogen-containing compounds and their use as glycine transport inhibitors
JP2005508940A (ja) アルツハイマー病の治療に有用なアリルアミド
MX2008015860A (es) Combinaciones que comprenden moduladores de 5ht6 e inhibidores de la colinesterasa.
JP2005535559A (ja) アルツハイマー病を治療するためのヒドロキシ置換アミド
JP2005514370A5 (enExample)
JP2002501039A5 (enExample)
WO2019193161A1 (en) Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
JP6498195B2 (ja) 代謝疾患を処置するためのppar節約化合物
MXPA04004903A (es) Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer.
RU2003101396A (ru) Замещенные нитрированные катехолы, их применение в лечении некоторых расстройств центральной и периферической нервной системы и содержащие их фармацевтические композиции
RU2005125047A (ru) Соединения карбоновых кислот
JP2006516629A (ja) 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法
JP2002540197A (ja) 抗菌剤
JP2002504134A (ja) 疼痛を治療するためのドラフラジン類似体の使用
JP2005514380A5 (enExample)
CN110845402B (zh) 吡啶亚甲基哌嗪衍生物及其用途